# Choosing Wisely recommendations in oncology: a scoping review

**Authors:** Fabiola Vasconcelos Alves, Elaine Barros Ferreira, Fabio Ynoe de Moraes, Safiya Karim, Paula Elaine Diniz dos Reis

PMC · DOI: 10.1007/s00520-026-10437-z · Supportive Care in Cancer · 2026-03-04

## TL;DR

This paper reviews oncology recommendations from the Choosing Wisely campaign, highlighting the need for personalized care and reducing unnecessary treatments.

## Contribution

The study provides a global mapping of oncology recommendations and emphasizes resource-stratified guidelines for better adoption.

## Key findings

- 220 recommendations were gathered from 19 studies and 20 international websites.
- Findings suggest a shift toward patient-centered, evidence-based oncology care.
- Resource-stratified guidelines are crucial for low- and middle-income countries.

## Abstract

Choosing Wisely (CW) campaign addresses the global challenge of reducing waste in healthcare by discouraging unnecessary interventions, minimizing harm, and promoting evidence-based care. Barriers like limited awareness among healthcare professionals and the lack of global mapping of recommendations hinder its implementation. We conducted a comprehensive scoping review mapping the literature on CW recommendations in oncology from 2012 to 2024. A total of 220 recommendations were gathered from 19 studies and 20 recognized international websites. These recommendations explored the importance of personalizing screening, staging, and treatment based on individual risk factors, such as life expectancy and biomarker status. The findings suggest a global shift toward patient-centered oncology care, focusing on personalized, evidence-based treatments and minimizing unnecessary interventions. Developing recommendations based on resource-stratified guidelines is vital for improving the adoption of CW, particularly in low- and middle-income countries, as it ensures that recommendations are aligned with local healthcare needs and available resources.

The online version contains supplementary material available at 10.1007/s00520-026-10437-z.

## Full-text entities

- **Genes:** CSF3 (colony stimulating factor 3) [NCBI Gene 1440] {aka C17orf33, CSF3OS, GCSF}, NPEPPS (aminopeptidase puromycin sensitive) [NCBI Gene 9520] {aka AAP-S, MP100, PSA}
- **Diseases:** colorectal cancer (MESH:D015179), thyroid cancer (MESH:D013964), cervical cancer (MESH:D002583), melanoma (MESH:D008545), prostate cancer (MESH:D011471), bone metastases (MESH:D009362), anxiety (MESH:D001007), gynecological cancers (MESH:D009369), lung cancer (MESH:D008175), breast cancer (MESH:D001943), cervical, ovarian, and endometrial cancers (MESH:D002575), breast, colorectal, prostate, and lung (MESH:D011472), febrile neutropenia (MESH:D064147), hematologic malignancy (MESH:D019337), oncology (MESH:D000072716)
- **Chemicals:** carbon (MESH:D002244)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12960452/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12960452/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12960452/full.md

---
Source: https://tomesphere.com/paper/PMC12960452